Crossmark

Transcriptomic profiling and machine learning uncover gene signatures of psoriasis endotypes and disease severity

Crossref DOI link: https://doi.org/10.1038/s43856-025-01325-4

Published Online: 2026-01-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rider, Ashley

Grantham, Henry J. https://orcid.org/0000-0002-3197-4823
Smith, Graham R. https://orcid.org/0000-0001-6967-7691
Watson, David S. https://orcid.org/0000-0001-9632-2159
Casement, John

Cockell, Simon J. https://orcid.org/0000-0002-6831-9806
Gisby, Jack

Foulkes, Amy C.

Henkin, Rafael https://orcid.org/0000-0002-5511-5230
Iqbal, Wasim A.

Ewen, Tom https://orcid.org/0000-0001-9178-9614
Amarnath, Shoba https://orcid.org/0000-0001-8081-8432
Ng, Sandra https://orcid.org/0000-0003-4524-6058
Zuliani, Paolo https://orcid.org/0000-0001-6033-5919
Dand, Nick https://orcid.org/0000-0002-1805-6278
Stocken, Deborah

Traini, Christopher

Thomas, Elizabeth

Kalyana-Sundaram, Shanker

Rajpal, Deepak K.

Smith, Kathleen M. https://orcid.org/0000-0001-7833-3102
Barker, Jonathan N.

Griffiths, Christopher E. M.

Di Meglio, Paola https://orcid.org/0000-0002-2066-7780
Smith, Catherine H. https://orcid.org/0000-0001-9918-1144
Warren, Richard B.

Barnes, Michael R. https://orcid.org/0000-0001-9097-7381
Reynolds, Nick J. https://orcid.org/0000-0002-6484-825X
,

Di Meglio, Paola
Funding

Funding for this research was provided by:

RCUK | Medical Research Council (MR/L011808/1)

Psoriasis Association

British Association of Dermatologists

Rosetrees Trust

UCB | UCB UK

British Skin Foundation

Sapienza Università di Roma (RP123188F6A67836)

AstraZeneca

Eli Lilly and Company

Janssen Research and Development

LEO Pharma Research Foundation

MedImmune

Novartis | Novartis Pharmaceuticals UK Limited

King's College London

Queen Mary University of London
License Information

Text and Data Mining valid from 2026-01-21

Version of Record valid from 2026-01-28
More Information

Article History

Received: 14 January 2025

Accepted: 9 December 2025

First Online: 21 January 2026

Competing interests

: N.J.R. has received, through Newcastle University, grants from Novartis and UCB outside the submitted work; travel support and/or consultancy income from AbbVie, Boehringer Ingelheim, Galderma, and UCB. M.R.B. has received research funding from Janssen and Benevolent AI, and consultancy with United Health group, Eli Lilly and Sanofi. All other authors declare no competing interests.

Document is current

Any future updates will be listed below